Marín García, Pablo JesúsLlobat Bordes, Maria DoloresMontaner Angoiti, EsperanzaProducción Científica UCH 2023UCH. Departamento de Producción y Sanidad Animal, Salud Pública Veterinaria y Ciencia y Tecnología de los AlimentosUCH. Departamento de Medicina y Cirugía Animal2024-07-152024-07-152023-01-29Montaner-Angoiti, E., Marín-García, P.J. & Llobat, L. (2023). Epigenetic alterations in canine malignant lymphoma: future and clinical outcomes. Animals, vol. 13, i. 3, art. 468 (29 jan.). DOI: https://doi.org/10.3390/ani130304682076-2615 (Electrónico)http://hdl.handle.net/10637/16063Este artículo pertenece al número especial "Companion Animals’ Molecular Oncology".Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic.enopen accessLinfomaslymphomasPerrosDogsTratamiento médicoMedical treatmentBiomarcadoresBiomarkersOncología veterinariaVeterinary oncologyArtículohttps://doi.org/10.3390/ani13030468https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es